SANTA MONICA, Calif. , Dec. 14, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary

SANTA MONICA, Calif. , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and

SANTA MONICA, Calif. , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today the appointment of Craig A.

SANTA MONICA, Calif. , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended September 30, 2020 , and

SANTA MONICA, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, is scheduled to present

Agreement   combines Opiant’s   opioid antagonist OPNT003 nasal nalmefene ,   with Apta r's   FD A-approved Unit   Dose System delivery device R einforces Opiant’s continued commitment to innovative overdose treatment options as America’s opioid epidemic worsen s OPNT003 nasal nalmefene remains on

SANTA MONICA, Calif. , Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its third quarter 2020 financial results after the financial

SANTA MONICA, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, is scheduled to

SANTA MONICA, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended June 30, 2020 , and provided a

SANTA MONICA, Calif. , July 23, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its second quarter 2020 financial results after the financial